Diurnal Expression of PD-1 on Tumor-Associated Macrophages Underlies the Dosing Time-Dependent Antitumor Effects of the PD-1/PD-L1 Inhibitor BMS-1 in B16/BL6 Melanoma-Bearing Mice.
Akito TsurutaYuki ShiibaNaoya MatsunagaMarina FujimotoYuya YoshidaSatoru KoyanagiShigehiro OhdoPublished in: Molecular cancer research : MCR (2022)
Selecting the most appropriate dosing time of PD-1/PD-L1 inhibitors may aid in developing cancer immunotherapy with higher efficacy.